Empagliflozin Attenuates Ferroptosis in Acute Myocardial Infarction via the AMPK/NRF2/SLC7A11 Signaling Pathway
Emerging evidence implicates ferroptosis in myocardial ischemic injury. This study aimed to investigate whether empagliflozin (EMP) suppresses ferroptosis in acute myocardial infarction (AMI) via the AMP-activated protein kinase (AMPK)/nuclear factor erythroid 2-related factor 2 (NRF2)/solute carrier family 7 member 11 (SLC7A11) pathway.
Authors
- Chunjun Liu (ORCID: https://orcid.org/0000-0002-4741-058X)
- Zhao Xiaoxia
- Xiangrui Tang
Institutions
- Yan'an University (CN)
- Baoji City Central Hospital (CN)
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- International Heart Journal
- Published
- 2026-07-30
- DOI
- https://doi.org/10.1536/ihj.25-386
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00